Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Oncotype DX

- PMLiVE

AstraZeneca’s heart failure treatment recommended by NICE for expanded use

More than 550,000 patients have a confirmed heart failure diagnosis in England alone

- PMLiVE

MSD and Eisai’s combination therapy recommended by NICE for advanced endometrial cancer

More than 9,700 people are diagnosed with womb cancer each year in the UK

- PMLiVE

AbbVie’s Rinvoq recommended by NICE for Crohn’s disease

It is estimated that over 155,000 adults are living with the condition in the UK

- PMLiVE

Kite’s CAR-T therapies recommended by NICE for certain blood cancers

The two treatments could benefit up to 600 patients each year in England

- PMLiVE

AstraZeneca’s Lynparza recommended by NICE for breast and prostate cancer

An estimated 800 patients will now be eligible for treatment with the drug

- PMLiVE

NICE publishes draft guidance not recommending Ipsen’s Cabometyx for thyroid cancer

Up to 15% of patients with differentiated thyroid cancer do not respond to radioactive iodine

- PMLiVE

AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma

An estimated 98,000 patients with severe uncontrolled asthma may be eligible for the new treatment

- PMLiVE

MSD’s Keytruda to be made available in England for advanced cervical cancer patients

Around 2,600 people are diagnosed with cervical cancer each year in England

Can Cinderella save us?

NICE sees ‘promise’ in four UTI tests that could help in fight against AMR

The tests can identify the presence of bacteria in a urine sample in less than 40 minutes

- PMLiVE

Novo Nordisk’s weight-loss drug recommended by NICE

The drug, semaglutide, will be offered to eligible adults for a maximum of two years

- PMLiVE

Eli Lilly’s Verzenio label expanded by FDA for early breast cancer patients

The decision removes the previous 20% Ki-67 score requirement for patient selection

- PMLiVE

NICE publishes final draft guidance recommending three COVID-19 treatments

The medicines have shown promise in treating COVID-19 and been found cost-effective

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links